Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | ARG1 | P05089 | 1/20 | 0.36 |
| ▸ | ARG2 | P78540 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.32 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28692014 | 0.98 | LMNA (0.39) | LMNAMEN1CYP2D6HRH1SCN1A | |
| SCHEMBL572174 | 0.79 | LMNA (0.43) | LMNAMEN1CYP2D6HRH1SCN1A | |
| SCHEMBL1088624 | 0.79 | ALDH1A1 (0.46) | LMNAMEN1CYP2D6HRH1SCN1A | |
| SCHEMBL27925056 | 0.77 | LMNA (0.42) | LMNAMEN1CYP2D6HRH1SCN1A | |
| Hydrochloric Acid SCHEMBL28461176 | 0.77 | LMNA (0.42) | LMNAMEN1CYP2D6HRH1SCN1A | |
| SCHEMBL14246961 | 0.77 | LMNA (0.42) | LMNAMEN1CYP2D6HRH1SCN1A | |
| SCHEMBL5645555 | 0.77 | ARG1 (0.33) | LMNAMEN1CYP2D6HRH1SCN1A | |
| Hydrochloric Acid SCHEMBL3553549 | 0.77 | ALDH1A1 (0.44) | LMNAMEN1CYP2D6HRH1SCN1A | |
| SCHEMBL28078060 | 0.76 | — | — | |
| SCHEMBL5226191 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101679422-A | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC | 2010-03-24 | — | — | CN | disclosed |
| CN-101420941-A | Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, and related combination therapies | ARENA PHARM INC (US) | 2009-04-29 | — | — | CN | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | LMNA 1837/4885MEN1 1745/4885CYP2D6 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.